QualityStocks would like to highlight ReGen Biologics, Inc. (OTCBB: RGBO). The company is an orthopedic products company that develops, manufactures and markets innovative tissue growth and repair products for U.S. and global markets. ReGen’s first approved product using its collagen scaffold technology is the Menaflex™ collagen meniscus implant.
In the company’s news yesterday,
ReGen Biologics announced that the U.S. Food and Drug Administration (FDA) has given the company clearance to market its collagen scaffold device, the Menaflex™ collagen meniscus implant. This device was designed to be used in surgical procedures for the reinforcement and repair of soft tissue injuries of the medial meniscus (a band that spans the knee joint).
Gerald E. Bisbee, Jr., Ph.D., Chairman and Chief Executive Officer of ReGen Biologics, stated, “We are extremely pleased that the FDA has considered the recommendations of the Orthopaedic and Rehabilitation Devices Advisory Panel in support of our collagen scaffold 510(k) and that the FDA agreed to enable U.S. marketing for this important product. Today’s announcement represents the culmination of many years of effort on the part of the Company and the invaluable contribution of many supportive investors, advisors and surgeons, as we sought to bring the Menaflex product to the U.S. market.”
He continued, “The potential market for ReGen’s Menaflex product includes a large portion of the estimated annual 1.3 million partial meniscectomies taking place world-wide and the growing backlog of patients who have undergone approximately 18 million partial meniscectomy procedures in the past 20 years. The incidence of partial meniscectomies increases for those patients who have had previous procedures. Approximately 65% of partial meniscectomies occur on the medial meniscus. The United States currently represents over 50% of the world market for meniscus procedures.”
“With over a decade of clinical experience, we are proud that the Menaflex is the first device cleared by the FDA for repair and reinforcement of medial meniscus tissue. We look forward to making this important product available to surgeons in the U.S. and giving them a potentially valuable new opportunity to provide benefit for their patients with first time or chronic meniscus injuries,” Dr. Bisbee stated in conclusion.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.